319 related articles for article (PubMed ID: 28859362)
21. Comparison of Definitive Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.
Yao B; Tan B; Wang C; Song Q; Wang J; Guan S; Jia Y; Ma Y; Huang X; Sun Y; Cheng Y
Ann Surg Oncol; 2016 Jul; 23(7):2367-72. PubMed ID: 26932711
[TBL] [Abstract][Full Text] [Related]
22. Randomised phase III trial of concurrent chemoradiotherapy with extended nodal irradiation and erlotinib in patients with inoperable oesophageal squamous cell cancer.
Wu SX; Wang LH; Luo HL; Xie CY; Zhang XB; Hu W; Zheng AP; Li DJ; Zhang HY; Xie CH; Lian XL; Du DX; Chen M; Bian XH; Tan BX; Jiang H; Zhang HB; Wang JH; Jing Z; Xia B; Zhang N; Zhang P; Li WF; Zhao FJ; Tian ZF; Liu H; Huang KW; Hu J; Xie RF; Du L; Li G
Eur J Cancer; 2018 Apr; 93():99-107. PubMed ID: 29494818
[TBL] [Abstract][Full Text] [Related]
23. Effect of Intensity Modulated Radiation Therapy With Concurrent Chemotherapy on Survival for Patients With Cervical Esophageal Carcinoma.
McDowell LJ; Huang SH; Xu W; Che J; Wong RKS; Brierley J; Kim J; Cummings B; Waldron J; Bayley A; Hansen A; Witterick I; Ringash J
Int J Radiat Oncol Biol Phys; 2017 May; 98(1):186-195. PubMed ID: 28258892
[TBL] [Abstract][Full Text] [Related]
24. Survival after definitive (chemo)radiotherapy in esophageal cancer patients: a population-based study in the north-East Netherlands.
Smit JK; Muijs CT; Burgerhof JG; Paardekooper G; Timmer PR; Muller K; Woutersen D; Mul VE; Beukema JC; Hospers GA; van Dijk BA; Langendijk JA; Plukker JT
Ann Surg Oncol; 2013 Jun; 20(6):1985-92. PubMed ID: 23274534
[TBL] [Abstract][Full Text] [Related]
25. Short-term response might influence the treatment-related benefit of adjuvant chemotherapy after concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients.
Liu A; Wang Y; Wang X; Zhu L; Nie Y; Li M
Radiat Oncol; 2021 Oct; 16(1):195. PubMed ID: 34600574
[TBL] [Abstract][Full Text] [Related]
26. Acute cardiac impairment associated with concurrent chemoradiotherapy for esophageal cancer: magnetic resonance evaluation.
Hatakenaka M; Yonezawa M; Nonoshita T; Nakamura K; Yabuuchi H; Shioyama Y; Nagao M; Matsuo Y; Kamitani T; Higo T; Nishikawa K; Setoguchi T; Honda H
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):e67-73. PubMed ID: 22365626
[TBL] [Abstract][Full Text] [Related]
27. Long-term results of definitive concurrent chemoradiotherapy using paclitaxel plus oxaliplatin in unresectable locally advanced esophageal cancer: a prospective phase II trial.
Song T; Zhang X; Fang M; Zhao R; Wu S
Cancer Med; 2016 Dec; 5(12):3371-3377. PubMed ID: 27925455
[TBL] [Abstract][Full Text] [Related]
28. The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma.
Malaisrie SC; Hofstetter WL; Correa AM; Ajani JA; Komaki RR; Rice DC; Vaporciyan AA; Walsh GL; Roth JA; Wu TT; Swisher SG
Cancer; 2006 Sep; 107(5):967-74. PubMed ID: 16874819
[TBL] [Abstract][Full Text] [Related]
29. Comparisons of survivals and toxicities between young and elderly patients with cervical cancer treated with definitive radiotherapy or concurrent chemoradiotherapy.
Wang W; Liu X; Meng Q; Zhang F; Hu K
Taiwan J Obstet Gynecol; 2019 May; 58(3):364-369. PubMed ID: 31122526
[TBL] [Abstract][Full Text] [Related]
30. A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma.
Zhao C; Lin L; Liu J; Liu R; Chen Y; Ge F; Jia R; Jin Y; Wang Y; Xu J
Oncotarget; 2016 Aug; 7(35):57310-57316. PubMed ID: 28087951
[TBL] [Abstract][Full Text] [Related]
31. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
32. [Outcomes and prognostic factors of advanced squamous cervical cancer after concurrent chemoradiotherapy].
Binbin T; Lingying W; Manni H; Jusheng A; Ning L
Zhonghua Fu Chan Ke Za Zhi; 2014 May; 49(5):348-54. PubMed ID: 25030731
[TBL] [Abstract][Full Text] [Related]
33. Triple-modality treatment in patients with advanced stage tonsil cancer.
Roden DF; Schreiber D; Givi B
Cancer; 2017 Sep; 123(17):3269-3276. PubMed ID: 28440876
[TBL] [Abstract][Full Text] [Related]
34. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma : A matched-pair multicenter analysis of outcomes.
Dong YY; Xiang C; Lu JX; Su YX; Pan YF; Cai R; Zhang RJ; He ZK; Liu ML; Huang H; Bai X; Tang HY; Shi YH; Wang Y; Jiang W
Strahlenther Onkol; 2016 Jun; 192(6):394-402. PubMed ID: 27215563
[TBL] [Abstract][Full Text] [Related]
35. Induction Chemotherapy plus Concurrent Chemoradiotherapy vs Concurrent Chemoradiotherapy in Elderly Patients with Advanced Nasopharyngeal Carcinoma.
Wang C; Tang X; Wang J; Song J; Xu Y
Otolaryngol Head Neck Surg; 2017 Aug; 157(2):233-238. PubMed ID: 28418781
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of complete response in patients with muscle-invasive bladder cancer undergoing concurrent chemoradiotherapy.
Wu CE; Lin YC; Hong JH; Chuang CK; Pang ST; Liaw CC
Anticancer Res; 2013 Jun; 33(6):2605-10. PubMed ID: 23749915
[TBL] [Abstract][Full Text] [Related]
37. Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery.
Lee JM; Yang SY; Yang PW; Shun CT; Wu MT; Hsu CH; Lin CC; Cheng JC; Wang YH; Chuang TH; Chen JS; Hsu HH; Huang PM; Kuo SW; Lee YC
Ann Surg Oncol; 2011 Jul; 18(7):2066-73. PubMed ID: 21298351
[TBL] [Abstract][Full Text] [Related]
38. High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy.
Cheng JC; Graber MS; Hsu FM; Tsai CL; Castaneda L; Lee JM; Chang DT; Koong AC
Ann Surg Oncol; 2014 Jul; 21(7):2361-8. PubMed ID: 24623035
[TBL] [Abstract][Full Text] [Related]
39. Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.
Spigel DR; Edelman MJ; O'Byrne K; Paz-Ares L; Mocci S; Phan S; Shames DS; Smith D; Yu W; Paton VE; Mok T
J Clin Oncol; 2017 Feb; 35(4):412-420. PubMed ID: 27937096
[TBL] [Abstract][Full Text] [Related]
40. Three-dimensional conformal radiotherapy with concurrent chemotherapy for postoperative recurrence of esophageal squamous cell carcinoma: clinical efficacy and failure pattern.
Bao Y; Liu S; Zhou Q; Cai P; Anfossi S; Li Q; Hu Y; Liu M; Fu J; Rong T; Li Q; Liu H
Radiat Oncol; 2013 Oct; 8():241. PubMed ID: 24139225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
